Physician profile
Zeba Barlas
NPI 1285642546
$3,046.13
in general payments reported to CMS, 2019-2025
18 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $371 · 2021: $213 · 2022: $548 · 2023: $439 · 2024: $665 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $757.75 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $750.74 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.72 | 2022-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $183.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $157.68 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $139.92 | 2019-2025 | Otezla, Repatha, Repatha |
| Phathom Pharmaceuticals, INC. | $139.59 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $112.20 | 2019-2023 | |
| Pfizer INC. | $95.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $83.33 | 2019-2023 | |
| Dexcom, INC. | $72.75 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $54.70 | 2022-2024 | Veozah |
| Sunovion Pharmaceuticals INC. | $52.95 | 2022 | |
| Exact Sciences Corporation | $48.33 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $38.26 | 2019-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $34.86 | 2019-2022 | |
| Abbott Laboratories | $23.32 | 2022 | |
| Cequr Corporation | $14.95 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeba Barlas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.